News

News

Events

OncXerna Therapeutics to Present at The LifeSci Partners Private Company Summer Symposium

Waltham, MA. July 19, 2021 – OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021. Please click the following link to register for the event: Register...

OncXerna Therapeutics to Present at Jefferies Virtual Healthcare Conference

Waltham, MA. May 18, 2021 – OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. The live presentation will occur on June 4, 2021 from 10:30 a.m. to 10:55 a.m. ET. A link to the live webcast...

OncXerna Therapeutics Provides New Results from its Xerna™ RNA-based Biomarker Platform at the AACR Annual Meeting

Waltham, MA. April 10, 2021 – OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today presented new results from its Xerna™ TME Panel during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting. In this study, OncXerna demonstrated that the first panel (TME Panel) from its Xerna™ platform revealed prognostic subtypes in colorectal cancer (CRC) by analyzing tumor samples from over 600 CRC patients. The Xerna™ TME Panel uses proprietary RNA-based gene expression data and a machine learning-based algorithm to classify patients based on their dominant biologies of the tumor microenvironment (TME), and has been developed as a clinical assay.

OncXerna Therapeutics to Participate at the Upcoming Investor Conferences

Waltham, MA. February 12, 2021 – OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will participate at the upcoming virtual investor conferences:

OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs

WALTHAM, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) — OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced the appointment of Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.